ACADIA Pharmaceuticals to Present at the Bio Emerging Company Investor Forum
SAN DIEGO, Oct. 7 /PRNewswire-FirstCall/ — ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that it will present at the Bio Emerging Company Investor Forum on Wednesday, October 13, at 2:20 pm PDT. ACADIA’s presentation will be given by Uli Hacksell, Ph.D., its Chief Executive Officer, and will be webcast from the Sheraton Palace Hotel in San Francisco.
A live webcast of ACADIA’s presentation will be accessible on the company’s website, www.acadia-pharm.com, under the investor relations section and an archived recording will be available on the website through October 27, 2004.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals is a biopharmaceutical company utilizing innovative science to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA currently has five drug programs in clinical and preclinical development directed at large unmet medical needs and major commercial markets, including Parkinson’s disease, schizophrenia, chronic pain, and glaucoma. Using its proprietary drug discovery platform, ACADIA has discovered all of the drug candidates in its product pipeline. ACADIA’s headquarters and biological research facilities are located in San Diego, California and its chemistry research facilities are located in Copenhagen, Denmark.
Contact:
ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, Vice President and Chief Financial Officer
+1 858-558-2871
ir@acadia-pharm.com